Abstract

255 Real-world identification of hepatically adjusted elexacaftor/tezacaftor/ivacaftor dosing trends at Atrium Health

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author

More From: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Paper Title
Journal
Date
Author
Clinical outcomes of two infants with cystic fibrosis, including presence of the vas deferens, born to a woman with cystic fibrosis taking CFTR modulators during both pregnancies
Aleksandra Kowalik ... Lena Hjelte
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society | VOL. -
Aleksandra Kowalik, et. al.Aleksandra Kowalik ... Lena Hjelte
13 Jun 2024
WS06.02 First-in-human clinical trial with SPL84, an ASO for treatment of cystic fibrosis patients carrying the 3849 +10 Kb C -> T mutation
E Kerem ... G Hart
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society | VOL. 23
E Kerem, et. al.E Kerem ... G Hart
01 Jun 2024
WS15.02 Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in people with cystic fibrosis and ELX/TEZ/IVA-responsive, non-F508del CFTR genotypes
M Mahic ... M Rice
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society | VOL. 23
M Mahic, et. al.M Mahic ... M Rice
01 Jun 2024
WS06.06 Safety and efficacy of a nebulized phage cocktail in cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infection: a phase 1b/2a randomized, double-blind, placebo-controlled study
E Kerem ... M Bassan
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society | VOL. 23
E Kerem, et. al.E Kerem ... M Bassan
01 Jun 2024
View more papers